Long-term use of mepolizumab in a case of chronic eosinophilic pneumonia: extending interval dosing.
J Asthma
; 61(1): 69-71, 2024 01.
Article
em En
| MEDLINE
| ID: mdl-37467753
ABSTRACT
INTRODUCTION:
Mepolizumab, a humanized anti IL-5 monoclonal antibody, has been used off-label for chronic eosinophilic pneumonia (CEP), inducing disease remission and saving systemic corticosteroids. CASE STUDY We present a case of CEP, requiring long-term corticosteroids therapy due to relapse upon withdrawal. Mepolizumab was started and maintained for 2 years and 6 months.RESULTS:
Corticosteroids could be withdrawn and mepolizumab dose interval was spared up to 10 wk with no disease relapse.CONCLUSION:
Mepolizumab is shown to be useful for chronic eosinophilic pneumonia, allowing corticosteroid withdrawal. Dose interval may be individualized under close monitoring, for a more efficient treatment, reducing medical costs while improving patients' quality of life.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Eosinofilia Pulmonar
/
Asma
/
Antiasmáticos
Limite:
Humans
Idioma:
En
Revista:
J Asthma
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Espanha